Markets:

Overview

News

Currencies

International

Treasuries

ADMA Biologics Inc - Common Stock (NQ:ADMA)

7.640 -0.260 (-3.29%)

Streaming Delayed Price Updated: 10:05 AM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ADMA Biologics Inc - Common Stock

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗

September 09, 2024

Via Benzinga

Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark ↗

September 05, 2024

Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86.

Via Investor's Business Daily

'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics ↗

August 30, 2024

"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road."

Via Benzinga

Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers ↗

August 29, 2024

Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers.

Via Investor's Business Daily

Biohaven Stock Earns Relative Strength Rating Upgrade ↗

August 21, 2024

Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91.

Via Investor's Business Daily

Assessing ADMA Biologics: Insights From 4 Financial Analysts ↗

August 12, 2024

Via Benzinga

How Is The Market Feeling About ADMA Biologics? ↗

July 11, 2024

Via Benzinga

Expert Ratings For ADMA Biologics ↗

July 09, 2024

Via Benzinga

SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating ↗

August 21, 2024

A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.

Via Investor's Business Daily

Immunome Stock Sees RS Rating Jump To 91 ↗

August 20, 2024

Immunome stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 88 to 91.

Via Investor's Business Daily

PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗

August 19, 2024

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

August 19, 2024

Via Benzinga

ADMA Biologics Announces Partial Paydown of Revolving Credit Facility

August 14, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

Lumen Tech & Upstart Are Among Top 7 Mid Cap Gainers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? ↗

August 11, 2024

Lumen, Upstart, ADMA, Sweetgreen, Veracyte, Clear Secure, and Core Scientific were best performers last week. Did you invest in them?

Via Benzinga

Expedia Posts Upbeat Earnings, Joins Akamai Technologies, Trade Desk, DXC Technology And Other Big Stocks Moving Higher On Friday ↗

August 09, 2024

Via Benzinga

ADMA Stock Earnings: ADMA Biologics Beats EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

ADMA stock results show that ADMA Biologics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

ADMA Biologics Announces Second Quarter 2024 Financial Results and Provides Business Update

August 08, 2024

From ADMA Biologics, Inc.

Via GlobeNewswire

Avadel Pharmaceuticals Stock Sees RS Rating Jump to 82 ↗

August 06, 2024

On Tuesday, Avadel Pharmaceuticals stock received a positive adjustment to its Relative Strength (RS) Rating, from 76 to 82.

Via Investor's Business Daily

ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024

August 01, 2024

Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET

From ADMA Biologics, Inc.

Via GlobeNewswire

Vir Biotechnology Stock Reaches 80-Plus RS Rating Benchmark ↗

July 26, 2024

On Friday, Vir Biotechnology stock had its Relative Strength (RS) Rating upgraded to 82, up from 64 a day earlier.

Via Investor's Business Daily

Beam Therapeutics Stock Earns RS Rating Jump To 85 ↗

July 24, 2024

On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85.

Via Investor's Business Daily

Jim Cramer Recommends Not Selling Vertiv, Says Buy This Social Media Stock 'Hand Over Fist' ↗

July 23, 2024

Mad Money's Jim Cramer recommends holding on to Vertiv Holdings, which is set to report its Q2 results before the opening bell on July 24.

Via Benzinga

Leslie's Issues Preliminary Financial Results, Joins Beyond Meat, Domino's And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

July 18, 2024

Via Benzinga

Biotech Arvinas Stock Earns 82 RS Rating ↗

July 17, 2024

The Relative Strength (RS) Rating for Arvinas stock entered a new percentile Wednesday, with a rise from 62 to 82.

Via Investor's Business Daily

Denali Therapeutics Stock Gets Technical Rating Upgrade ↗

July 16, 2024

Denali Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating

Via Investor's Business Daily

3 Millionaire-Making Stock Picks With Astounding Growth Potential ↗

July 13, 2024

Owning millionaire-making stocks can be a life changer. Look no further than these three companies which are full of potential.

Via InvestorPlace

Bull Run Alert: 3 Stocks Set to Soar in the Coming Months ↗

July 11, 2024

Get ready for the next bull run with these stocks. All three are showing impressive growth and massive returns.

Via InvestorPlace

UroGen Pharma Stock Earns 91 RS Rating ↗

June 27, 2024

UroGen Pharma stock had its Relative Strength (RS) Rating upgraded to 91 Thursday, up from 87 a day earlier.

Via Investor's Business Daily

Arcellx Stock Earns Relative Strength Rating Upgrade ↗

June 21, 2024

One key metric to look for in a stock is an 80-plus Relative Strength Rating. Arcellx stock cleared that benchmark Friday, jumping to 83.

Via Investor's Business Daily

Intra-Cellular Therapies Stock Scores RS Rating Upgrade To 87 ↗

June 20, 2024

Intra-Cellular Therapies sees its Relative Strength Rating enter the 80-plus level.

Via Investor's Business Daily

< Previous 1 2

...

4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.